Skip to content
Clinical Trials – home

Praxis für Prävention und Therapie Prof. Dr. med. Stephan Jacob

Research site

Germany Brombeerweg 6, 78048 Villingen-Schwenningen, Germany

  • 1 trial recruiting
  • Obesity · Overweight
  • Adult patients

About Specializations

Praxis für Prävention und Therapie Prof. Dr. med. Stephan Jacob in Villingen-Schwenningen, Germany specialises in clinical trials of conditions such as Obesity, Overweight, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The research program at Praxis für Prävention und Therapie Prof. Dr. med. Stephan Jacob evaluates cardiovascular disease outcomes in individuals with type 2 diabetes mellitus, seeking to lower the risk of heart attacks, strokes, and related events through innovative therapies.

  • Assessment of major adverse cardiac events
  • Comparison of new glucose‑lowering agents with standard care
  • Exploration of cardiovascular safety in high‑risk populations

The site’s focus on heart health aligns with its broader commitment to improving outcomes for patients with metabolic disorders.

Nutritional and Metabolic Diseases

Clinical investigations target chronic weight management and broader metabolic health, testing novel medications designed to produce durable weight loss and improve metabolic control.

  • Evaluation of sustained body‑weight reduction
  • Impact on glucose regulation and insulin sensitivity
  • Safety and tolerability of long‑term metabolic therapies

Praxis für Prävention und Therapie Prof. Dr. med. Stephan Jacob leverages its expertise to advance treatment options for patients struggling with obesity and related metabolic conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Brombeerweg 678048 Villingen-SchwenningenGermany
Recruiting now
1 trial
Conditions studied
2

More sites in Villingen-SchwenningenGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

2 clinical trials

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+1

Not recruiting

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.